Impact Factor
3.14
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.40
5,248 total citations
h5-index
102
h5 depth signal
Cited share
19.0%
762 of 4,009
Total citations
5,248
Citation footprint
Metric signal
1.28
External metric anchor
Self-citation
4.2%
220 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
2,559
China
1,522
Japan
986
United Kingdom
623
Canada
573
Citing Fields of Research
Lung Cancer
19,635
Oncology
4,958
Immunology
4,097
Cancer & Development
1,230
Mesothelioma & Asbestosis
823
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
30,155
Articles tracked across the journal lifetime
Indexed publication set
4,009
762 cited publications
Last 12 months
2,318
193.2 publications/month
Open access share
2.5%
58 OA publications in the last year
Leading citing country
United States
2,559 citing publications
Leading citing field
Lung Cancer
19,635 citing publications
Latest tracked publication
14 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Jan. 2006-
v1n1, Jan. 2006-
Research Focus & Classification
Indexed Subjects
Lung Cancer
Issuing & Sponsoring Bodies
Contributor
International Association for the Study of Lung Cancer
Broad Categories
Neoplasms
Pulmonary Medicine
Lung Cancer
MeSH Descriptors
Thoracic Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/j.jtho.2026.105238
Open DOI
P3.069: Predictive Analysis of Lung Cancer Patient-Derived Organoids Drug Responses
02
03
DOI 10.1016/j.jtho.2026.105156
Open DOI
P2.378: Intrathecal Pemetrexed Plus EGFR-TKI for Osimertinib-Refractory Leptomeningeal Metastasis in EGFR-Mutant NSCLC
04
05
06
DOI 10.1016/j.jtho.2026.105153
Open DOI
P2.375: Neoadjuvant Sacituzumab Tirumotecan Plus Aumolertinib in Resectable EGFR-Mutant NSCLC: A Phase II Trial
07
DOI 10.1016/j.jtho.2026.105311
Open DOI
P3.142: SENLOAD Study: Association of Baseline CD8 T-Cell Senescence With Survival in Unresectable Stage III NSCLC
08
09
10
Bibliographical & Catalog Notes
Title from cover.
Latest issue consulted: Vol. 1, no. 3 (Mar. 2006).
Also issued online.
Complemented by (work): JTO clinical and research reports 2666-3643 (OCoLC)1143696075 (DNLM)101769967.
v. 1, no. 1 (Jan 2006)20070330 Notice not published Printed on acid-free paper